|Mr. Glenn Mario Saldanha||Chairman, Chief Exec. Officer and Managing Director||108.46M||N/A||47|
|Mrs. Cherylann Maria Pinto B.Pharm||Exec. Director of Corp. Affairs and Exec. Director||33.37M||N/A||50|
|Mr. P. Ganesh||Pres and Global Chief Fin. Officer||N/A||N/A||N/A|
|Dr. Fred Grossman D.O., FAPA||Pres and Chief Medical Officer||N/A||N/A||N/A|
|Mr. Kanish Malik||Pres and Global Head of Operations||N/A||N/A||N/A|
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, Latin America, Europe, the United States, and internationally. The company provides active pharmaceutical ingredients in the therapeutic areas of alimentary track, anti-infective, anti-parasitic, cardiovascular, central nervous system, dermatological, genito-urinary, musculo-skeletal, respiratory, and others; and formulations in the therapeutic areas of dermatology, respiratory, cardiovascular, anti- diabetic, and oncology. Its products include Crofelemer for HIV related diarrhea; and is in Phase III clinical trials for adult acute infectious diarrhea, including cholera. The companys products under development comprise GRC 17536 that is in Phase II clinical trial for neuropathic pain and respiratory disorders; GRC 15300, which is in Phase II clinical trial for neuropathic pain; GBR 830 for autoimmune disorders; GBR 900 for chronic pain; and Vatelizumab (GBR 500), a biological molecule for multiple sclerosis. The company was founded in 1977 and is headquartered in Mumbai, India.
Glenmark Pharmaceuticals Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.